Discovery of novel Bruton’s tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text

Immunology, Pathology, Immunologic Mechanism +16

The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

David Vetrie, Igor Vořechovský, Paschalis Sideras et al. · Nature · 1993 · 1.5K citations

Protein Function, Signal Transduction, Molecular Physiology +14

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

Satoshi Tsukada, Douglas C. Saffran, David J. Rawlings et al. · Cell · 1993 · 1.3K citations

Autoimmune Disease, Receptor Tyrosine Kinase, Malignant Blood Disorder +8

Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

Julie A. Di Paolo, Tao Huang, Mercedesz Balázs et al. · Nature Chemical Biology · 2010 · 328 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +11

RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents

Daigen Xu, Yong Kim, Jennifer Postelnek et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 140 citations